Phase I trial of ICV-delivered bivalent CAR T-cells in glioblastoma скачать в хорошем качестве

Phase I trial of ICV-delivered bivalent CAR T-cells in glioblastoma

Stephen Bagley, MD, MSCE, University of Pennsylvania, Philadelphia, PA, discusses results from the Phase I trial (NCT05168423) of bivalent CAR T-cells targeting EGFR and IL13Rα2 intracerebroventricularly (ICV) delivered in recurrent glioblastoma (rGBM). Treatment was generally feasible, with expected neurotoxicities and evidence of robust CAR T-cell expansion in cerebrospinal fluid. Many patients experienced measurable tumor shrinkage, with one durable stable disease case exceeding one year. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.